ClinicalTrials.gg
RecruitingNCT01957267FSOCTUpdated Sep 9, 2026

Functional and Structural Imaging for Glaucoma

An observational study in Glaucoma, sponsored by Oregon Health and Science University. Recruiting at 1 site in United States. Open to participants aged 40 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Oregon Health and Science University · Observational

From the registry’s dates

  • Started Sep 2013; still recruiting 13 years 1 month later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
249
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 490 studies in Glaucoma with a site in United States — 77 open to participants now, 96 under way, 5 of them phase 3. Glaucoma · United States.

Planned enrollment
18th of 110
249 · median 100
Started
2013
with 22 others
Observational
110 of 490
19 open now
Primary completion
2031-05
later than 92 of 95 live
Registered
210th of 490
by date

Among the 490 studies in Glaucoma with a site in United States, this one is the 18th largest by planned enrollment of the 110 observational ones, is one of 23 that started in 2013, is one of 110 observational ones, reaches primary completion later than 92 of the 95 other live ones, and was the 210th registered.

By phase

490 studies; the count open now beside each. This study's row is marked.

No phase163 · 36 open
Observationalthis study110 · 19 open
Phase 266 · 4 open
Phase 466 · 9 open
Phase 346 · 5 open
Phase 117 · 2 open
Phase 1/217 · 2 open
Phase 2/35 · 0 open

By the year they started

First in 1976; this study’s year is marked. 23 started in 2013.

Size and results

Median enrollment 79 across the 364 interventional studies, 100 across the 110 observational. Of the 356 that completed or were terminated, 138 (39%) have results posted.

Was this useful?
Watch this landscapeDownload CSVWith an account: a weekly mail of what changed among 490 studies in Glaucoma with a site in United States, or all of them as a file.
02

Study summary

The specific aims of the clinical studies are to:

  • Develop a directional high-resolution OCT and OCT angiography prototype to improve imaging of structure and perfusion.
  • Validate wide-field OCT and OCT angiography parameters to improve early glaucoma detection.
  • Simulate visual field results by combining structural and angiography OCT data.
  • Assess abilities of above technologies and OCT-derived parameters on predicting glaucoma detection, conversion, and progression.
Read the detailed description

Glaucoma is the second leading cause of blindness in the US. The diagnosis and monitoring of glaucoma are important problems, not only because of its prevalence, but also because of its silent and irreversible nature. However all of the current diagnostic tests have serious limitations. Although elevated intraocular pressure (IOP) is a risk factor, most glaucoma patients actually have IOP within normal range. Visual field (VF) tests are poorly reproducible, and a series of 3 tests are needed to establish diagnosis or confirm progression. Although ophthalmoscopic examination can detect optic nerve head (ONH) and nerve fiber layer (NFL) defects, reliability in diagnosis and tracking is hampered by its subjective and semi-quantitative nature. Although quantitative imaging with optical coherence tomography (OCT), scanning laser polarimetry (SLP), and confocal scanning laser ophthalmoscopy (cSLO) can more objectively detect ONH and NFL defects, their diagnostic accuracies are still not sufficient to be relied on alone for diagnostic screening. It has been estimated that about half of glaucoma patients in the US do not know that they have the disease. Thus, there is a need for improvements in glaucoma diagnostic technologies. One approach that deserves further exploration is blood flow imaging.

There is much circumstantial evidence that vascular factors play important roles in the pathophysiology of glaucoma:

  1. Systemic vasculopathy increases the risk of developing glaucoma. Hypertension, diabetes, and vasospastic conditions are all known risk factors. Normal tension glaucoma has also been linked to peripheral endothelial dysfunction and erectile dysfunction. This suggests that poor circulation may be a causative factor or a facilitative factor that predisposes the ONH to damage by elevated IOP.
  2. Decrease or fluctuation in ocular perfusion pressure was identified as an independent risk factor for progression in the Collaborative Normal-Tension Glaucoma Study and other studies. Nocturnal hypotension is also a risk factor for glaucoma progression.
  3. Medications that improve ocular perfusion appear to have protective effects that are not explained by the lowering of IOP.
  4. Optic disc hemorrhage and peripapillary atrophy are both associated with accelerated glaucoma progression. These finding may support a role for focal ischemia.
  5. Animal experiments show that increased IOP causes decreased ONH blood flow in the presence of low systemic blood pressure.

Despite the evidence, the management of glaucoma remains focused on the lowering of IOP, the one causative factor that responds to treatment and can be easily measured. Blood flow measurement is a research topic, but currently has no clinical role in the diagnosis, prognostic evaluation, or treatment of glaucoma. Therapies aimed at improving ocular circulation cannot be effectively developed without a practical method for quantitative and reproducible evaluation of ONH and retinal perfusion. Thus there is a great need to develop better technology for the evaluation of ocular circulation.

Using high-speed OCT systems, we have developed new methods to image and measure optic nerve head (ONH) and retinal blood flow. Preliminary results showed that VF loss was more highly correlated with retinal blood flow as measured by OCT than any neural structure measured by OCT or other imaging modality. Accordingly, the goal of the proposed project is to improve the diagnostic and prognostic evaluation of glaucoma by further developing novel functional OCT measurements using ultrahigh-speed (70-100 kHz) OCT technology.

Retinal blood flow, ONH circulation, optic disc rim volume, peripapillary nerve fiber layer volume, and macular ganglion cell complex volume are all pieces of the same glaucoma puzzle. This project will develop novel imaging methods that allow us to look at the whole picture using one tool - ultrahigh-speed OCT.

03

Conditions studied

  • Glaucoma

Browse trials for

Keywords

  • Glaucoma
  • Optical Coherence Tomography
  • Intraocular pressure
  • Optic nervehead
  • Nerve fiber layer
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study will enroll both males and females and include all ethnic and racial groups through clinical practices in the centers. The study will enroll subjects in the older adult age range commonly affected by glaucoma - 40 years or older. The study will exclude people with life-threatening or debilitating illness that would make 5-year participation unlikely or cooperation with tests difficult. For similar reasons those older than 85 years are excluded. The study also excludes those with any disease that might confound the diagnosis of glaucoma. Otherwise people with any health status are eligible for enrollment. Two groups of participants are recruited in the study: healthy controls or participants with confirmed glaucoma.

Eligibility criteria

Inclusion Criteria: Normal Subjects (both eyes must meet all criteria)

  1. No history or evidence of retinal pathology or glaucoma
  2. Normal Humphrey 24-2 VF: A mean defect (MD), corrected pattern standard deviation (CPSD) within 95% limits of normal reference, and glaucoma hemifield test (GHT) within normal limits (97%).
  3. Intraocular pressure \< 21 mm Hg
  4. Central corneal pachymetry > 500 microns
  5. No chronic ocular or systemic use
  6. Open angle (gonioscopy must show 75% or more of the angle to be Grade 2 or more by Shaffer's grading system)
  7. Normal appearing ONH and NFL: vertical and horizontal cup/disc ratio (CDR) ≤ 0.5 and intact neuroretinal rim without peripapillary hemorrhages, notches, localized pallor, or NFL defect
  8. Symmetric ONH between left and right eyes: CDR difference \< 0.2 in both vertical and horizontal dimensions

Inclusion criteria: Glaucoma Group

  1. ONH or NFL defect visible on slit-lamp biomicroscopy defined as one of following:

    1. diffuse or localized thinning of the rim
    2. disc (splinter) hemorrhage
    3. notch in the rim
    4. vertical cup/disc ratio greater than the fellow eye by > 0.2
  2. Presence or absence of VF defects as measured by Humphrey SITA 24-2 VF.

Exclusion Criteria: All Groups

  1. Best-corrected visual acuity less than 20/40
  2. Age \< 40 or >85 years
  3. Refractive error of > +3.00 D or \< -7.00 D
  4. Previous intraocular surgery except for uncomplicated keratorefractive surgery and cataract extraction with posterior chamber intraocular lens implantation
  5. Diabetic retinopathy
  6. Other diseases that may cause VF loss or optic disc abnormalities
  7. Inability to clinically view or photograph the optic discs due to media opacity or poorly dilating pupil
  8. Inability to perform reliably on automated VF testing
  9. Life-threatening or debilitating illness making it unlikely patient could successfully complete the study.
  10. Refusal of or of commitment to the full length of the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
249 participants (estimated)
Patient registry
No

Groups and cohorts

  • Glaucoma Group

    Patients with clinically confirmed glaucomatous ONH or NFL defects, with or without VF abnormalities

  • Normal Group

    Volunteers with healthy eyes

06

What researchers measure

Primary outcomes

  1. Measure of retinal non-perfusion areas in mm2

    Time frame: 5 years

  2. Measure vessel density in percentage (%)

    Time frame: 5 years

  3. Determine accuracy of sector visual field progression in OCT-based sector visual field simulation compared to actual visual field results. Measured in dB change over time.

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
  • Oregon Health & Science University, Casey Eye Institute
    Portland, Oregon 97214, United States
    Recruiting
    • Chinmay Deshpande, M.Optom. · Contactdeshpanc@ohsu.edu · 503-494-9628
    • Denzil Romfh, OD · Contactromfhd@ohsu.edu · 503-494-4351
    • Beth Edmunds, MD, PhD · Sub investigator
    • Shandiz Tehrani, MD, PhD · Sub investigator
    • Jeffrey Healey, MD · Sub investigator
    • David Huang, MD, PhD · Sub investigator
    • Ellen Davis, MD · Sub investigator
    • Seema Gupta, MD · Sub investigator
    • Eleisa Ing, MD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2013 (actual). Primary completion is estimated for May 2031, 212 months after the start.

Of 110 non-industry observational studies under Glaucoma, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 208. This study's planned 212 months is above that.

Counting every sponsor, half of 134 studies reached it within 31 months; a quarter within 12 and three quarters within 208.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2013
First posted
Oct 8, 2013
StartActual
Sep 25, 2013
Primary completionEst.
May 31, 2031
CompletionEst.
May 31, 2031
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01957267
Responsible party
David Huang (Aiyin Chen, MD, Professor of Ophthalmology, Oregon Health & Science University, Oregon Health and Science University) — Principal investigator
First posted
Oct 8, 2013
Start date
Sep 25, 2013
Primary completion
May 31, 2031 (estimated)
Completion
May 31, 2031 (estimated)
Last update
Sep 9, 2026

Study contacts

Chinmay Deshpande, M.Optom.
Contact
deshpanc@ohsu.edu
503-494-9628
Denzil Romfh, OD
Contact
romfhd@ohsu.edu
503-494-4351
Aiyin Chen, MD
principal investigator · Oregon Health and Science University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion